APA (7th ed.) Citation

Lu, Y., Liao, L., Du, K., Mo, J., Zou, X., Liang, J., . . . Tan, Y. (2024). Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma. BMC Cancer, 24(1), 1. https://doi.org/10.1186/s12885-024-11848-z

Chicago Style (17th ed.) Citation

Lu, Yinghao, et al. "Clinical Activity and Safety of Sintilimab, Bevacizumab, and TMZ in Patients with Recurrent Glioblastoma." BMC Cancer 24, no. 1 (2024): 1. https://doi.org/10.1186/s12885-024-11848-z.

MLA (9th ed.) Citation

Lu, Yinghao, et al. "Clinical Activity and Safety of Sintilimab, Bevacizumab, and TMZ in Patients with Recurrent Glioblastoma." BMC Cancer, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12885-024-11848-z.